Does not appear to be any update for the sepsis or Covid/Flu A/Flu B space in the Report. That concerns me, as the life sciences update seems to be more geared towards to acquisitions rather than development of new tests.
EDIT: "Cessation and realignment of resources from existing clinical developments (COVID-19, Multiplex, PCT) to assay development, due to regulatory and market conditions."
Ann: Company Update, page-2
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.002(8.70%) |
Mkt cap ! $52.28M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $20.83K | 964.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2247357 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 164375 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |